newsfilter
← Latest News
ClinicalTrials.gov·

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma - NCT05618366

Maximum-tolerated dose (MTD) determination (Part 1), Number of participants who experience dose-limiting toxicities (DLTs), Number of participants who experience adverse events (AEs), from baseline to 30 days after the last dose of study drug, as assessed by CTCAE v5.0, (and 7 more...)